子癇前症診断薬市場規模、シェア、成長分析：検査タイプ別、製品別、エンドユーザー別、地域別 - 産業予測 2025～2032年

子癇前症診断薬市場規模は2023年に10億9,000万米ドルと評価され、2024年の11億2,000万米ドルから2032年には14億3,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは3.1％で成長する見通しです。

世界の子癇前症診断薬市場は、妊産婦の健康をめぐる意識の高まりと妊娠関連合併症の複雑さに牽引され、大きな成長を遂げています。重篤な高血圧性疾患である子癇前症は産科医療に大きなリスクをもたらすため、正確で早期診断法の需要が高まっています。その結果、主要な市場関係者は、早期発見と早期管理の改善を目指した診断技術の革新を進めています。医療費の増加、新興市場におけるヘルスケアインフラの強化、産科医療への先端医療技術の導入といった要因が、市場の拡大をさらに後押ししています。しかし、高度な診断法のコストが高いことや、地域によっては医療アクセスが限られていることが課題となっています。新規バイオマーカーや非侵襲的診断法の研究が進んでいることから、市場は当面継続的な発展を遂げるものと思われます。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• ケーススタディ
• 技術の進歩

子癇前症診断薬市場規模：検査タイプ別& CAGR（2025-2032）

• 市場概要
• 血液検査
• 尿検査
• その他

子癇前症診断薬市場規模：製品別& CAGR（2025-2032）

• 市場概要
• 機器
• 消耗品

子癇前症診断薬市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院
• 専門クリニック
• 診断センター
• その他

子癇前症診断薬市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Diabetomics Inc.（United States）
• DRG Instruments GmbH（Germany）
• F. Hoffmann-La Roche Ltd（Switzerland）
• PerkinElmer Inc.（United States）
• Siemens Healthineers AG（Germany）
• Thermo Fisher Scientific（United States）
• GE Healthcare（United States）
• Abbott Laboratories（United States）
• Acon Laboratories, Inc.（United States）
• Arkray, Inc.（Japan）
• Bio-Rad Laboratories, Inc.（United States）
• Cardinal Health（United States）
• Danaher Corporation（Beckman Coulter, Inc.）（United States）
• DIRUI Industrial Co., Ltd.（China）
• Metabolomic Diagnostics Ltd.（Ireland）
• Sera Prognostics（United States）
• Synlab Group（Germany）
• Microlife Corporation（Switzerland）
• Bayer AG（Germany）
• Progenity Inc.（United States）

結論と提言

Preeclampsia Diagnostics Market size was valued at USD 1.09 billion in 2023 and is poised to grow from USD 1.12 billion in 2024 to USD 1.43 billion by 2032, growing at a CAGR of 3.1% during the forecast period (2025-2032).

The global preeclampsia diagnostics market is experiencing significant growth, driven by heightened awareness surrounding maternal health and the complexities of pregnancy-related complications. As preeclampsia, a serious hypertensive condition, poses substantial risks in obstetrics, the demand for precise and early diagnostic methods is escalating. Consequently, major market players are innovating diagnostic technologies aimed at improving early detection and management. Factors such as rising healthcare expenditures, enhancements in healthcare infrastructure in emerging markets, and the incorporation of advanced medical technologies in obstetric care are further propelling market expansion. However, high costs of sophisticated diagnostic methods and limited healthcare access in certain regions may pose challenges. With ongoing research into novel biomarkers and non-invasive diagnostics, the market is poised for continued advancements in the foreseeable future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Preeclampsia Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Preeclampsia Diagnostics Market Segments Analysis

Global Preeclampsia Diagnostics Market is segmented by Test Type, Product, End-user and region. Based on Test Type, the market is segmented into Blood Tests, Urine Analysis and Others. Based on Product, the market is segmented into Instruments and Consumables. Based on End-user, the market is segmented into Hospitals, Specialty Clinics, Diagnostic Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Preeclampsia Diagnostics Market

The Preeclampsia Diagnostics market is driven by the challenges associated with accurately diagnosing the condition in pregnant women. A solitary increase in blood pressure is not a definitive indicator of preeclampsia, complicating the diagnosis process. Furthermore, many expectant mothers lack awareness of preeclampsia and its associated risks, which can lead to hypertension during pregnancy going undetected until it escalates, thereby restricting timely intervention opportunities. This gap in knowledge not only poses significant health risks to the women affected but also heightens the likelihood of increased infant mortality rates, underscoring the urgent need for effective diagnostic solutions and education.

Restraints in the Preeclampsia Diagnostics Market

The preeclampsia diagnostics market faces significant challenges due to the complexities involved in diagnosing the condition in pregnant women. A mere increase in blood pressure is not a definitive indicator of preeclampsia, making accurate identification difficult. Furthermore, a considerable number of expectant mothers lack knowledge about preeclampsia, which severely limits their understanding of the associated risks. As hypertension often goes undetected until more severe symptoms arise, this oversight restricts timely intervention options. The resultant unawareness poses considerable risks to maternal health and significantly heightens infant mortality rates, emphasizing the critical need for improved awareness and diagnostic methods in this area.

Market Trends of the Preeclampsia Diagnostics Market

The global preeclampsia diagnostics market is witnessing a significant trend towards early risk assessment for pregnant women, propelling the adoption of biomarker-based tests designed for the early detection of this condition. By focusing on specific biological markers, healthcare providers can more accurately identify potential preeclampsia cases, which enables timely interventions crucial for improving maternal and fetal health outcomes. This proactive diagnostic approach aligns with the overarching goals of healthcare systems to enhance maternal care and reduce the adverse effects of preeclampsia on pregnancies. As awareness and demand for early intervention grow, the market for innovative diagnostic solutions is expected to flourish in tandem.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Preeclampsia Diagnostics Market Size by Test Type & CAGR (2025-2032)

• Market Overview
• Blood Tests
• Urine Analysis
• Others

Global Preeclampsia Diagnostics Market Size by Product & CAGR (2025-2032)

• Market Overview
• Instruments
• Consumables

Global Preeclampsia Diagnostics Market Size by End-user & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty Clinics
• Diagnostic Centers
• Others

Global Preeclampsia Diagnostics Market Size & CAGR (2025-2032)

• North America (Test Type, Product, End-user)
  • US
  • Canada
• Europe (Test Type, Product, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Test Type, Product, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Test Type, Product, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Test Type, Product, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Diabetomics Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DRG Instruments GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acon Laboratories, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arkray, Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (Beckman Coulter, Inc.) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DIRUI Industrial Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Metabolomic Diagnostics Ltd. (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sera Prognostics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Synlab Group (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Microlife Corporation (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Progenity Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations